Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care
Funded by: National Institute on Alcohol Abuse and Alcoholism
Project dates: August 2013 - April 2019
Principal Investigator: Lee, Joshua D.

This study evaluated the effectiveness of a newer form of naltrexone, injectable extended-release naltrexone, for primary care alcohol treatment. Comparative and cost effectiveness data from this study will inform the integration of alcohol medical management treatment into the patient-centered medical home, and possibly expand alcohol pharmacotherapies to persons not otherwise accessing specialty treatment.

Abstract on NIH RePORTER
Related Publications
Malone M, McDonald R, Vittitow A, Chen J, Obi R, Schatz D, Tofighi B, Garment A, Goldfeld K, Gold H, Laska E, Rotrosen J, Lee JD (2019).
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)
Contemporary Clinical Trials, 81, 102-109. doi: 10.1016/j.cct.2019.04.006. PMCID: PMC6701869.

Friedmann PD, Wilson D, Nunes EV, Hoskinson R, Lee JD, Gordon M, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O'Brien CP (2018).
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
Journal of Substance Abuse Treatment, 85, 61-65. doi: 10.1016/j.jsat.2017.01.018. PMCID: PMC5565721.